-
GenFleet Therapeutics to Present Updated Clinical Data Highlighting Novel Oncology Agents at 2026 ASCO Annual Meeting
>>
-
AACR 2026: GenFleet Therapeutics Announces Data of VS-7375/GFH375 from Partner Verastem Oncology’s Preclinical Studies, Demonstrating Superior Potency, Durable Pathway Control, and Rational Mechanism-supported Combinations for KRAS G12D–Mutant Cancers
>>
-
AACR 2026: GenFleet Therapeutics Presents Preclinical Data of GFS784 (EGFR-Pan-RAS ADC), the First Asset from Its Innovative FAScon™ ADC Platform, Demonstrating Potent Activity in RAS-Mutant, EGFR-Mutant and TKI-Resistant Tumors at AACR 2026
>>
-
AACR 2026: GenFleet Therapeutics Announces Preclinical Data of GFH276, a Molecular Glue Pan RAS (ON) Inhibitor, Demonstrates Lower Preclinical Effective Dose and Synergistic Efficacy with Multiple Standard-of-care Therapies
>>
-
AACR 2026: GenFleet Therapeutics Announces Preclinical Data of GFH603, a Molecular Glue-like Allosteric Activator of KEAP1-CUL3 Complex, Targeting Key RAS Pathway Co-mutations to Block NRF2-driven Resistance and Enhance Standard-of-Care Therapeutic Efficacy
>>
-
GenFleet Therapeutics Receives Second Breakthrough Therapy Designation (BTD) for GFH375, as the First KRAS G12D Inhibitor Monotherapy Included in China’s BTD List for Pancreatic Cancer Treatment
>>
-
Phase II Data from GenFleet Therapeutics’KROCUS Study of Fulzerasib Combined with Cetuximab Featured in Lancet Oncology, Establishing the World’s First KRAS+EGFR Dual-Target Approach for First-Line NSCLC
>>
-
Innovative Therapeutic Modalities for RAS-Mutant and Co-Mutated Tumors: GenFleet Announces Data from Three Preclinical Studies Selected for Poster Presentation of 2026 AACR Annul Meeting
>>
